BG104868A - CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF - Google Patents

CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF

Info

Publication number
BG104868A
BG104868A BG104868A BG10486800A BG104868A BG 104868 A BG104868 A BG 104868A BG 104868 A BG104868 A BG 104868A BG 10486800 A BG10486800 A BG 10486800A BG 104868 A BG104868 A BG 104868A
Authority
BG
Bulgaria
Prior art keywords
polypeptides
polynucleotides
vectors
compositions
afore
Prior art date
Application number
BG104868A
Other languages
Bulgarian (bg)
Other versions
BG65066B1 (en
Inventor
Bernd Dorken
Gert Riethmuller
Peter Kufer
Ralf Lutterbuse
Ralf Bargou
Anja Loffler
Original Assignee
Micromet Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micromet Ag filed Critical Micromet Ag
Publication of BG104868A publication Critical patent/BG104868A/en
Publication of BG65066B1 publication Critical patent/BG65066B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Described are novel single-chain malfunctional polypeptides comprising at least two binding sites specific for the CD19 and CD3 antigen, respectively. Further provided are polypeptides, wherein the above-described polypeptide comprises at least one further domain, preferably of pre-determined function. Furthermore, polynucleotides encoding said polypeptides as well as to vectors comprising said polynucleotides and host cells transformed therewith and their use in the production of said polypeptides are described. In addition, compositions, preferably pharmaceutical and diagonostic compositions are provided comprising any of the afore-described polypeptides, polynucleotides or vectors. Described is also the use of the afore-mentioned polypeptides, polynucleotides and vectors for the preparation of pharmaceutical compositions for immunotherapy, preferably against B-cell malignancies such as non-Hodgkin lymphoma. 31 claims
BG104868A 1998-04-21 2000-10-17 CD19xCD3 SPECIFIC POLYPEPTIDES AND USE THEREOF BG65066B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE98107269 1998-04-21

Publications (2)

Publication Number Publication Date
BG104868A true BG104868A (en) 2001-09-28
BG65066B1 BG65066B1 (en) 2007-01-31

Family

ID=38057577

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104868A BG65066B1 (en) 1998-04-21 2000-10-17 CD19xCD3 SPECIFIC POLYPEPTIDES AND USE THEREOF

Country Status (1)

Country Link
BG (1) BG65066B1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2982696T (en) * 2008-11-07 2019-06-04 Amgen Res Munich Gmbh Treatment of acute lymphoblastic leukemia

Also Published As

Publication number Publication date
BG65066B1 (en) 2007-01-31

Similar Documents

Publication Publication Date Title
EP1348715A3 (en) CD19xCD3 specific polypeptides and uses thereof
CA2072249A1 (en) Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
WO1995016038A3 (en) Humanized antibodies and uses thereof
SG96535A1 (en) Pharmaceutical composition for the treatment or prevention of a malignant tumor
WO2000018921A3 (en) Synthetic peptides having fgf receptor affinity
CA2172376A1 (en) Antibodies to cd40
AU2821195A (en) Cross-reacting monoclonal antibodies specific for e-selectin and p-selectin
GB9206422D0 (en) Antibody preparation
EP0739350A4 (en) Ligand that binds fas antigen
AU7272491A (en) Tris-maleimido compounds as intermediates in trifunctional antibody synthesis
GR3026219T3 (en) Mouse monoclonal antibodies
AU1378395A (en) Metal chelators
DE69824023D1 (en) PEPTIDES THAT ARE AGONISTS OR ANTAGONISTS OF CARCINOEMBRIONAL ANTIGENS (CEA)
IL72394A0 (en) Protected tripeptides useful in the synthesis of pentapeptides
WO1997029199A3 (en) Prostate specific antigen peptides and uses thereof
BG104868A (en) CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF
EP0972054A4 (en) Enhancement of immune response using targeting molecules
EP1200476A4 (en) Antitumor antibodies, proteins, and uses thereof
AU622548B2 (en) Novel tumor-associated antigen, antibodies, compositions and uses therefor
SI1027375T1 (en) Anti-idiotypic monoclonal antibodies, their use in the active immunotherapy of malignant tumors, and compositions containing them
WO2002020567A3 (en) Mammalian cystatin-8 and its use to inhibit cancer procoagulant protein
ES2088820A1 (en) Antipneumolysin monoclonal antibodies
AU2003204088A1 (en) Anti-idiotypic monoclonal antibodies, their use in the active immunotherapy of malignant tumors, and compositions containing them
WO2002050274A3 (en) Seleno-cysteine containing protein zsel1